AtriCure (ATRC)
(Delayed Data from NSDQ)
$36.66 USD
+1.65 (4.71%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $36.69 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATRC 36.66 +1.65(4.71%)
Will ATRC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATRC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATRC
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
ATRC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Other News for ATRC
50 Day Moving Average Support appears for ATRC after 2.64% move
Is ATRC poised for gains? 50 Day Moving Average Support shows up after gaining 3.84%
Atricure Executive Makes a Significant Stock Sale!
Insider Sell: Justin Noznesky Sells 3,000 Shares of AtriCure Inc (ATRC)
Technical picture remains unchanged for ATRC after it falls 1.25% on September 15